Journal of Inflammation Research最新文献

{"title":"Robust Predictive Performance of MLPAS and CCMLP for Clinical Outcome and Risk Stratification in Patients with Colorectal Cancer.","authors":"Qiu-Ying Ye, Yuan-Yuan Wang, Zhi-Jie Wang, Min Lu, Hong-Xin Peng, Xin Wang, Xue-Xin Cheng, Hou-Qun Ying","doi":"10.2147/JIR.S498028","DOIUrl":"10.2147/JIR.S498028","url":null,"abstract":"<p><strong>Background: </strong>There is no recognized biomarker is recommended to monitor or predict the prognosis of colorectal cancer (CRC) patients with negative detection of carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9) and to classify high recurrence-risk cases.</p><p><strong>Methods: </strong>Discovery and two-stage validation cohorts, which included 2111 radically resected patients with stage II-III CRC, were enrolled in this study. We detected preoperative peripheral monocyte, platelet, albumin (Alb), pre-albumin (pAlb), CEA, and CA19-9 and investigated the prognostic and risk-stratified roles of twelve new inflammatory biomarkers in the three cohorts.</p><p><strong>Results: </strong>In our study, monocyte-to-pAlb ratio (MPAR), monocyte-to-lymphocyte -to-Alb ratio (MLAR), monocyte-to-lymphocyte-to-pAlb ratio (MLPAR), monocyte- to-pAlb score (MPAS), lymphocyte-to-monocyte-Alb score (MLAS), lymphocyte-to monocyte-pAlb score (MLPAS), and platelet-to-lymphocyte-Alb score (PLAS) were significantly associated with both RFS and OS in three cohorts. MLPAS showed the best performance in predicting RFS and OS, and it was related to right-tumor location and significant cancer burden (≥5cm) in the overall population. Moreover, MLPAS is a robust prognostic biomarker in subgroups stratified by CEA or CA19-9. Patients with scores zero and two of the CEA-CA19-9-MLPAS score (CCMLP) showed the lowest and highest recurrence and death rates, respectively, and significant survival differences were observed between them.</p><p><strong>Conclusion: </strong>MLPAS is an optimal, independent, and robust prognostic biomarker in the stage II-III CRC population, especially with negative CEA or CA19-9. The CCMLP could effectively classify high recurrence-risk patients who require more focus, monitoring, and treatment for the clinic.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"3889-3900"},"PeriodicalIF":4.2,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of <i>RSAD2</i> as a Key Biomarker Linking Iron Metabolism and Dendritic Cell Activation in Systemic Lupus Erythematosus Through Bioinformatics and Experimental Validation.","authors":"Hengrong Qian, Sheng Gao, Ting Zhang, Yuanyuan Xie, Siyan Chen, Yanggang Hong, Xinlei Wu, Zhouhang Xing, Lingjie Kong, Jintao Mo, Yiming Lin, Anzhe Zheng, Wenqian Wang, Liangxing Wang, Chunyan Hua","doi":"10.2147/JIR.S500115","DOIUrl":"10.2147/JIR.S500115","url":null,"abstract":"<p><strong>Background: </strong>Systemic lupus erythematosus (SLE) is characterized by aberrant immune activation and disrupted iron metabolism, yet the molecular mediators that govern both processes remain unclear. This study aims to identify pivotal genes that modulate immune responses and iron metabolism, and to delineate their contributions to SLE pathogenesis.</p><p><strong>Methods: </strong>Differentially expressed genes related to iron metabolism (IM-DEGs) were identified using datasets (GSE72326, GSE110169, GSE126307, and GSE50772) from the GEO database and the MSigDB. Functional enrichment analyses were performed on the iron metabolism related genes (IM-Genes). A weighted gene co-expression network analysis was constructed to identify hub genes, which were further refined as potential biomarkers using the least absolute shrinkage and selection operator method. The predictive value of these biomarkers was validated using receiver operating characteristic (ROC) curves and the nomogram. CIBERSORT was employed to evaluate immune cell infiltration in SLE. Additionally, the expression and function of <i>RSAD2</i> were confirmed using RNA interference, quantitative real-time PCR, and Western blotting techniques.</p><p><strong>Results: </strong>Bioinformatics analyses identified 4 potential biomarkers: <i>RSAD2, MT2A, LCN2</i>, and <i>LTF. RSAD2</i> exhibited the highest clinical validity (AUC = 0.927) and was closely associated with classic diagnostic indicators. Its diagnostic potential was confirmed through ROC curve and nomogram, highlighting its role in SLE pathogenesis. Elevated <i>RSAD2</i> expression was observed in peripheral blood mononuclear cells of SLE patients, positively correlating with activated dendritic cells (DCs). Notably, <i>Rsad2</i> knockdown markedly impaired the function of activated DCs, as evidenced by suppressed expression of inflammatory mediators and iron metabolism-related genes.</p><p><strong>Conclusion: </strong>Our findings suggest that <i>RSAD2</i> is a potential diagnostic biomarker and therapeutic target for SLE, elucidating the intricate relationship between immune dysregulation and aberrant iron metabolism in activated DCs, which exacerbates SLE.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"3859-3878"},"PeriodicalIF":4.2,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Involvement in Idiopathic Inflammatory Myopathies.","authors":"Hongji Zhu, Runzhao Li, Hongxia Tan, Tangdan Ding, Ying Yuan, Zhihua Wen, Jijun Zhao, Min Liu, Qiong Shi, Liubing Li","doi":"10.2147/JIR.S503928","DOIUrl":"10.2147/JIR.S503928","url":null,"abstract":"<p><p>Idiopathic inflammatory myopathies (IIMs) are a group of autoimmune diseases that includes the main subtypes dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and inclusion body myositis. IIMs are characterized by the involvement of skeletal muscle and multiple organs, including the heart. This review summarizes the pathology, prevalence, biomarkers, imaging and treatment of cardiac involvement in patients with IIMs. The cardiac involvement in these patients is usually subclinical and rarely considered as the main clinical feature at the time of initial consultation, with a prevalence ranging from 4% to 26%. However, it results in a worse prognosis and represents the main cause of mortality in patients with IIMs. The selection of specific serum cardiac biomarkers is essential for the early detection of cardiac involvement in patients with IIMs, such as cardiac troponin I (cTnI), which is preferred over cardiac troponin T (cTnT), followed by diagnostic evaluations including electrocardiography (ECG), echocardiography (ECHO), and cardiac magnetic resonance imaging (CMR). The combination of glucocorticoids, immunosuppressants, and conventional cardiac medications is effective for the management of IIM patients with confirmed cardiac involvement.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"3879-3888"},"PeriodicalIF":4.2,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tryptase as a Biomarker for Adverse Prognosis in ST-Segment Elevation Myocardial Infarction Patients: A Prospective Cohort Study.","authors":"Pengxin Xie, Shuwan Xu, Xi Chen, Hong Xu, Ruitao Zhang, Dan Li, Lijie Sun, Dan Zhu, Ming Cui","doi":"10.2147/JIR.S502496","DOIUrl":"10.2147/JIR.S502496","url":null,"abstract":"<p><strong>Background: </strong>Acute ST-segment elevation myocardial infarction (STEMI) is characterized by a rapid inflammatory response, with mast cells (MCs) playing a significant role. However, the relationship between MC activation and the adverse outcomes remains unclear. This study investigated the association between the MC activation biomarker, tryptase, and major adverse cardiovascular events (MACE).</p><p><strong>Methods: </strong>This prospective study included patients with STEMI who underwent primary percutaneous coronary intervention (PPCI) at Peking University Third Hospital between July 2020 and July 2023. Tryptase levels were detected from plasma samples collected 6 hours post-PPCI and using ELISA method. All patients were followed up every 6 months, with MACE as the primary endpoint.</p><p><strong>Results: </strong>The study enrolled 514 patients with STEMI who underwent PPCI (mean age: 59.27 ± 13.26 years, 16.93% female). The median follow-up time was 13.28 (10.47-37.61) months, during which 85 patients (16.54%) experienced MACE. Patients in the higher tryptase group had a higher risk of MACE (HR 2.60 [1.68-4.01], P < 0.001). Tryptase was an independent risk factor of MACE (HR 1.56 [1.29-1.88] per 1-unit increase, P < 0.001). Subgroup analysis revealed the prognostic value of tryptase among different age groups, left ventricular ejection levels, and patients with hypertension, hyperlipidemia, smoking and diabetes. The addition of tryptase to the basic model had an incremental effect on the predictive value for MACE (AUC: 0.763 vs 0.702, P = 0.002).</p><p><strong>Conclusion: </strong>In this study, elevated tryptase levels, a biomarker of MC activation, were identified as a significant predictor of MACE in STEMI patients undergoing PPCI.</p><p><strong>Trial registration: </strong>(ClinicalTrials.gov NCT05802667).</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"3817-3828"},"PeriodicalIF":4.2,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11917165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic Profiling and Clinical Insights: The Role of MMP9 in Differentiating Psoriasis Vulgaris from Generalized Pustular Psoriasis.","authors":"Ting Gong, Jiawen Chen, Zhixun Xiao, Renwei Luo, Zequn Tong, Hui Ke, Zhao Liu, Cuirong Xiao, Niu Xiang, Chao Ji","doi":"10.2147/JIR.S495044","DOIUrl":"10.2147/JIR.S495044","url":null,"abstract":"<p><strong>Background: </strong>Generalized pustular psoriasis (GPP) constitutes a rare, severe inflammatory disorder that differs from psoriasis vulgaris (PV). The IL-36 pathway has been identified as a key element in GPP pathogenesis.</p><p><strong>Objective: </strong>To explore protein expression between PV and GPP, providing insights into potential mechanisms.</p><p><strong>Methods: </strong>We performed proteomic analysis of tissue specimens from patients with PV and GPP to identify differentially expressed proteins. Comparative analysis of the proteomic data was performed and proteins with significant differences were further identified using immunofluorescence and Western blot techniques. Differential proteins were also explored by evaluating the efficacy of IL-36R inhibitors before and after GPP treatment, providing potential avenues for targeted therapeutic strategies.</p><p><strong>Results: </strong>Tissue proteomic profiling showed that matrix metallopeptidase 9 (MMP9) increased significantly in the GPP as compared to PV. Immunofluorescence and Western blot analysis confirmed that MMP9 is higher expressed in GPP. And after therapy with IL-36 inhibitors showed that the level of MMP9 expression was markedly reduced.</p><p><strong>Conclusion: </strong>MMP9 may be involved with the pathogenesis of GPP.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"3795-3805"},"PeriodicalIF":4.2,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Clinical Predictive Model Based on SOCS3 Promoter Methylation to Predict the Prognosis of Acute-on-Chronic Hepatitis B Liver Failure.","authors":"Ji-Hui Li, Yuna Tang, Jing Wang, Xue-Fei Wei, Na Wang, Jing-Wei Wang, Hui Lyu, Xue-Mei Jiang, Hui-Hui Liu, Kai Wang","doi":"10.2147/JIR.S506050","DOIUrl":"10.2147/JIR.S506050","url":null,"abstract":"<p><strong>Purpose: </strong>The study aimed to quantitatively detect the suppressors of cytokine signaling (SOCS) 3 promoter methylation levels, investigate the relationship between SOCS3 methylation and gene expression, and construct a prognosis prediction model combined with clinical indicators for Acute-on-chronic Hepatitis B Liver Failure (ACHBLF).</p><p><strong>Methods: </strong>A total of 135 ACHBLF patients were enrolled and randomly divided into the training cohort and validation cohort. The SOCS3 mRNA and promoter methylation in peripheral blood mononuclear cells (PBMCs) of ACHBLF patients were quantitative measured. A clinical prediction model was established based on SOCS3 promoter methylation and clinical indicators. The prediction model was evaluated by the area under the receiver operating characteristic curve, the Hosmer-Lemeshow (H-L) goodness-of-fit test, and decision curve analysis.</p><p><strong>Results: </strong>In this study, compared with ACHBLF survivals, SOCS3 showed lower mRNA levels and higher methylation levels in ACHBLF non-survivals. The SOCS3 methylation rates were negatively correlated with SOCS3 mRNA levels. PT-INR, IL-6, and percentage of the methylation reference (PMR) value (SOCS3) were used to establish a clinical model for predicting ACHBLF patients' prognosis. The results of AUC, the Hosmer-Lemeshow (H-L) goodness-of-fit test and decision curve analysis (DCA) showed that the prediction model had good clinical applicability. The prediction model was visualized.</p><p><strong>Conclusion: </strong>A prognosis prediction model for ACHBLF was developed based on PMR (SOCS3), PT-INR and IL-6, which may have a good potential clinical application value.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"3741-3756"},"PeriodicalIF":4.2,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Evaluation of Lipocalin-2 in Sepsis-Associated Encephalopathy via Machine Learning Approaches.","authors":"Jia Hu, Ziang Chen, Jinyan Wang, Aoxue Xu, Jinkai Sun, Wenyan Xiao, Min Yang","doi":"10.2147/JIR.S504390","DOIUrl":"10.2147/JIR.S504390","url":null,"abstract":"<p><strong>Purpose: </strong>Sepsis-associated encephalopathy (SAE) critically contributes to poor prognosis in septic patients. Identifying and screening key genes responsible for SAE, as well as exploring potential targeted therapies, are vital for improving the management of sepsis and advancing precision medicine.</p><p><strong>Patients and methods: </strong>Single-cell RNA sequencing (scRNA-seq) was administrated to identify cell subpopulations related to poor prognosis in septic patients. Next, hierarchical dynamic weighted gene co-expression network analysis (hdWGCNA) was employed to identify genes associated with specific neutrophil subpopulations. Enrichment analysis revealed the biological functions of these genes. Subsequently, neuroinflammation-related genes were obtained to construct a neuroinflammation-related signature. The AddModuleScore algorithm was used to calculate neuroinflammation scores for each cell subpopulation, whereas the CellCall algorithm was used to assess the crosstalk between neutrophils and other cell subpopulations. To identify key genes accurately, four binary classification machine learning algorithms were utilized. Finally, Western blotting and behavioral tests were used to confirm the role of LCN2-related neuroinflammation in septic mice.</p><p><strong>Results: </strong>This study utilized scRNA-seq to reveal the critical role of peripheral neutrophils during sepsis, identifying these neutrophils as contributors to poor prognosis and associated with neuroinflammation. On the basis of various machine learning algorithms, we discovered that Lipocalin-2 (LCN2) may be the key gene involved in neutrophil-induced SAE. To prove these findings, we conducted in vivo experiments and an animal model. Increased LCN2 expression and cognitive dysfunction occurred in septic mice. Additionally, the levels of markers of astrocytes and microglia and inflammatory factors such as TNF-α and IL-6 were significantly increased. All these phenomena were reversed by the downregulation of LCN2.</p><p><strong>Conclusion: </strong>The upregulation of LCN2 expression on peripheral neutrophils is a critical step that triggers neuroinflammation in the central nervous system during SAE.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"3843-3858"},"PeriodicalIF":4.2,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unilateral Biportal Endoscopic Debridement and Drainage for Lumbar Infectious Spondylodiscitis: A Retrospective Study and Preliminary Results.","authors":"Rupeng Chu, Wei Cui, Wenjin Chen, Yin Zhuang, Guoyong Yin, Wei Peng, Shujun Zhang","doi":"10.2147/JIR.S505707","DOIUrl":"10.2147/JIR.S505707","url":null,"abstract":"<p><strong>Background: </strong>Clinical management of lumbar infectious spondylodiscitis is challenging due to its variable presentation and complex course, and its treatment remains controversial. This study aims to evaluate the clinical efficacy of unilateral biportal endoscopic (UBE) debridement and drainage for treating lumbar infectious spondylodiscitis.</p><p><strong>Methods: </strong>We retrospectively analysed sixteen patients diagnosed with lumbar infectious spondylodiscitis who underwent UBE debridement and drainage between April 2022 and July 2023. Biopsy specimens were sent to the laboratory to identify pathogens immediately after surgeries. Clinical outcomes were assessed by the visual analog scale (VAS) scores of the back, Oswestry Disability Index (ODI), the modified MacNab criteria (MNC), and regular serological tests at pre- and post-operation.</p><p><strong>Results: </strong>Fourteen patients (87.5%) experienced a significant improvement in their clinical symptoms. Their VAS and ODI scores significantly improved compared to those before the operation throughout the follow-up (p<0.05). The modified MNC at the last follow-up indicated that 87.50% of these participants were rated excellent or good. Causative bacteria were identified in 13 (81.25%) of 16 biopsy specimens. At the final follow-up, all patients' kyphotic angle changes were less than 10° without spinal instability. A 12-month follow-up CT scan revealed bony intervertebral fusion in 10 cases (62.5%). The postoperative regular serological tests were significantly improved than before surgery (p< 0.05). No recurrent infections or significant surgery-related complications were observed during postoperative follow-up.</p><p><strong>Conclusion: </strong>UBE surgery was successful in debridement, back pain relief, and bacteriologic diagnosis of lumbar infectious spondylodiscitis. This procedure could be an effective alternative for patients when conservative treatments fail.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"3695-3704"},"PeriodicalIF":4.2,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Nomogram Based on Tumor Response to Induction Chemotherapy and Plasma Epstein-Barr Virus DNA Level after Induction Chemotherapy to Explore Individualized Treatment of Patients with Locally Advanced Nasopharyngeal Carcinoma.","authors":"Fushuang Liu, Chengxian Ma, Meiwen Chen, Kaihua Chen, Liru Zhu, Ling Li, Xiaodong Zhu, Song Qu, Chang Yan","doi":"10.2147/JIR.S507926","DOIUrl":"10.2147/JIR.S507926","url":null,"abstract":"<p><strong>Purpose: </strong>To explore the influence of Epstein-Barr virus (EBV) DNA levels before and after induction chemotherapy (IC), tumor response to IC, and baseline factors on overall survival (OS) in patients with locally advanced nasopharyngeal carcinoma (LA-NPC). A nomogram was subsequently constructed to explore the individualized optimal cumulative cisplatin dose (CCD) in concurrent chemoradiotherapy (CCRT).</p><p><strong>Methods: </strong>A total of 581 LA-NPC patients were included, randomly divided into training and validation cohorts in a 7:3 ratio. In the training cohort, a nomogram was subsequently established based on multivariate Cox regression analysis and then validated. Subsequently, patients were classified into different risk groups based on the nomogram, and the impact of different levels of CCD on survival outcomes was evaluated.</p><p><strong>Results: </strong>EBV DNA levels after IC, tumor response to IC, age, and LDH were independent prognostic factors of OS. Schoenfeld residual analysis indicated overall satisfaction of the proportional hazards assumption for the Cox regression model. The C-index of the nomogram was 0.758 (95% CI: 0.695-0.821) for the training cohort and 0.701 (95% CI: 0.589-0.813) for the validation cohort. Calibration curves demonstrated good correlation between the nomogram and actual survival outcomes. DCA confirmed the clinical utility enhancement of the nomogram over the TNM staging system. For OS, patients in the medium/high-risk group with a CCD > 200 mg/m² had better outcomes than those with CCD ≤ 200 mg/m², although the difference was not statistically significant (<i>p</i> = 0.097). No significant difference was observed in local relapse-free survival (LRFS), distant metastasis-free survival (DMFS), and progression-free survival (PFS) across various levels of CCD in different risk subgroups (<i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>The nomogram based on EBV DNA levels after IC, tumor response, LDH, and age effectively predicts OS in LA-NPC patients, aids in risk stratification, and may guide treatment decisions.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"3677-3693"},"PeriodicalIF":4.2,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of PLIN3 in Prognosis and Tumor-Associated Macrophage Infiltration: A Pan-Cancer Analysis.","authors":"Shaohua Yang, Hejie Liu, Youbin Zheng, Hongyu Chu, Zhuming Lu, Jie Yuan, Shengshan Xu","doi":"10.2147/JIR.S509245","DOIUrl":"10.2147/JIR.S509245","url":null,"abstract":"<p><strong>Background: </strong>Nucleolar and spindle-associated protein 1 (PLIN3), a member of the perilipin family, plays a critical role in lipid droplet dynamics and is implicated in promoting tumor progression across several cancers. However, its influence on the tumor immune microenvironment and its potential as a prognostic indicator regarding immunotherapy responses have yet to be systematically evaluated. This study leverages data retrieved from multiple databases to address these questions.</p><p><strong>Methods: </strong>PLIN3 mRNA and protein expressions were analyzed across a diverse range of normal and cancerous tissues, utilizing data retrieved from multiple databases. The potential of PLIN3 as a diagnostic and prognostic biomarker in cancers was assessed. Advanced computational algorithms were employed to examine the impact of PLIN3 on immune cell infiltration. The association between PLIN3 expression and the presence of M2 macrophages was validated through analyses incorporating bulk and single-cell transcriptomics, spatial transcriptomics, and multicolor fluorescence staining techniques. Furthermore, the effects of PLIN3 on tumor malignancy and growth were investigated in vitro in lung adenocarcinoma (LUAD) cells. Potential compounds targeting PLIN3 were identified using the Connectivity Map (cMap) web tool, and their efficacy was further assessed through molecular docking.</p><p><strong>Results: </strong>PLIN3 was predominantly upregulated in various cancers, correlating with adverse prognostic outcomes. A strong positive association was observed between PLIN3 levels and M2 macrophage infiltration in several cancer types, establishing it as a potential pan-cancer marker for M2 macrophage presence. This was confirmed by integrative multi-omics analysis and multiple fluorescence staining. Additionally, PLIN3 knockdown in LUAD cells diminished their malignant traits, resulting in decreased proliferation and migration. In LUAD, clofibrate was identified as a potential inhibitor of PLIN3's pro-oncogenic functions.</p><p><strong>Conclusion: </strong>PLIN3 may serve as a potential biomarker and oncogene, particularly in LUAD. It plays a key role in mediating M2 macrophage infiltration in various cancers and presents a promising immunotherapeutic target.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"3757-3777"},"PeriodicalIF":4.2,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}